Search

Camphor

The FDA ruled that camphorated oil could not be marketed in the United States and that no product could contain a concentration higher than 11%. … When ingested, camphor has a rapid onset of toxic effects, and camphorated oil is the product most often responsible for its toxicity.

Selexipag

PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. … Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.

Milnacipran

(BACE-1), which has investigationally been associated with β-amyloid plaque formation - making the agent a possible course of treatment for Alzheimer's disease [A175957]. … Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment

Eszopiclone

[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity[A179827], offering a safer alternative to other drugs used for insomnia. … Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia.

Tolperisone

It possesses a high affinity for nervous system tissue, reaching highest concentrations in brain stem, spinal cord and peripheral nerves.

Cobamamide

This drug is available as a nutritional supplement to prevent vitamin B12 deficiency. Vitamin B12 is a collective term for these variously substituted corrinoids. … It is therefore important to treat vitamin B12 deficiency with a combination of MeCbl and AdCbl or hydroxocobalamin or cobalamin [L2054].

Avilamycin